FGEN FibroGen Corporation: Enterprise Value to EBITDA Ratio
Efficient drug delivery to pharmacy chains guarantees patients global access to therapy. This chart of stock quotes on the GURU.Markets platform for FibroGen, Inc. (FGEN) shows an EV/EBITDA metric of 0.00, which complements the revenue data from roxadustat sales supported by AstraZeneca and Astellas. The business is currently undergoing a stage of aggressive cost optimization and a search for local partners, having completely abandoned large-scale mergers.
Comprehensive metric breakdowns and analytics for fibrogen.com (FGEN)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
- financial results and valuation multiples details:
FGEN - Final Profit|Expected Profit FibroGen, Inc.|FGEN - Market Cap to Earnings|Forward P/E Multiple FibroGen, Inc.|FGEN - Price to Net Income Growth Ratio|EV/EBITDA Multiple FibroGen Corporation|FGEN - Profit before interest, taxes and amortization|Earnings per share for the last twelve months FibroGen|FGEN - Earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months fibrogen.com|FGEN - Earnings per share increase in current year|Earnings growth forecast for next year FibroGen, Inc.
Fundamental valuation:FibroGen Corp FGEN
The expansion strategy of the FibroGen, Inc. (FGEN) therapeutic pipeline and the licensing of formulas to pharma behemoths are directly reflected in the company's dynamic EV/EBITDA ratio. This metric compares the total enterprise value, including debt obligations, against operating profit, allowing investors to assess the real value of assets and the risks of capital impairment due to debt load during business scaling.
Analysis of competing companies
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ANIP (ANI Pharmaceuticals, Inc.)|MNKD (MannKind Corp) - Company Value to Operating Income Before Depreciation Ratio|Amphastar - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Pacira Corp PCRX|SPRY: EV/EBITDA Multiple|TBPH (theravance.com) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aquestive Therapeutics, Inc.|SCPH: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tectonic Therapeutic, Inc. (TECX)|TNXP - Company Value to EBITDA|EV/EBITDA Multiple SXTC (China SXT Pharmaceuticals, Inc.)|Enterprise Value to EBITDA Multiple Eupraxia Pharmaceuticals, Inc.|BioHarvest Sciences Inc. - EV/EBITDA Multiple|Company Value to EBITDA Invizyne Technologies|oramed.com (ORMP) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation ENTX|Enterprise Value to EBITDA Ratio HYFT|ABVC: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple CPIX|Total Company Value to Operating Income Before Depreciation Ratio Quantum BioPharma Ltd.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Telomir Pharma TELO|RANI: Enterprise Value to Operating Income Before Depreciation|Synergy CHC Corporation - EV/EBITDA Multiple|Rallybio Corporation (RLYB) - Enterprise Value to EBITDA Ratio|LEXX (lexariabioscience.com) - Enterprise Value to EBITDA Ratio|PULM - Total Company Value to Operating Income Before Depreciation Ratio|PTHL (Pheton Holdings Limited) - EV/EBITDA Multiple|Aptorum - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple LYRA|impactbiomedinc.com (IBO) - Enterprise Value to EBITDA Multiple|EV/EBITDA Multiple TNFA (TNF Pharmaceuticals, Inc.)|cbdMD Inc. (YCBD) - Company Value to EBITDA|PRFX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CYTO (Altamira Therapeutics) - Enterprise Value to Operating Income Before Depreciation|Lipella Pharmaceuticals (LIPO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio OPTN (optinose.com)|PIRS (Pieris Pharmaceuticals, Inc.) - EV/EBITDA Multiple|PROC: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple PTPI|EV/EBITDA Multiple Qilian International Corp (QLI)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Acelyrin, Inc. SLRN|Business Value to Operating Income Before Depreciation TFFP
